Markets:

Overview

News

Currencies

International

Treasuries

Altimmune, Inc. - Common Stock (NQ:ALT)

5.913 +0.253 (+4.47%)

Streaming Delayed Price Updated: 1:07 PM EST, Jan 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Altimmune, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Earnings Scheduled For May 13, 2025 ↗

May 13, 2025

Via Benzinga

What to Expect from Altimmune's Earnings ↗

May 12, 2025

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

May 05, 2025

Via Benzinga

What's Going On With Altimmune (ALT) Stock Today? ↗

May 02, 2025

Altimmune shares jumped 8.5% on Friday. The stock is higher ahead of next week's presentation at the European Association for the Study of the Liver International Liver Congress.

Via Benzinga

Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? ↗

April 30, 2025

Via The Motley Fool

What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday? ↗

April 14, 2025

Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid obesity drug competition.

Via Benzinga

Altimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗

March 03, 2025

Via Benzinga

Earnings Scheduled For February 27, 2025 ↗

February 27, 2025

Via Benzinga

Altimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗

January 23, 2025

Via Benzinga

8 Analysts Assess Altimmune: What You Need To Know ↗

April 03, 2025

Via Benzinga

Buying These Dirt-Cheap Stocks Could Be a Brilliant Move ↗

March 22, 2025

Via The Motley Fool

Altimmune Shares Sink This Year, But Retail Traders See A Buyout On The Horizon ↗

March 19, 2025

A Betaville report suggested Altimmune has begun a strategic review with an adviser, with speculation that three major pharmaceutical firms may be involved.

Via Stocktwits

Altimmune Expands Weight-Loss Drug Pemvidutide's Potential To Alcohol-Related Disorders ↗

March 14, 2025

Altimmune plans Phase 2 trials in 2025 for pemvidutide in alcohol use disorder and liver disease, highlighting weight loss and liver health benefits.

Via Benzinga

This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗

February 28, 2025

Via Benzinga

Earnings Scheduled For November 12, 2024 ↗

November 12, 2024

Via Benzinga

Decoding 4 Analyst Evaluations For Altimmune ↗

August 22, 2024

Via Benzinga

Altimmune Retail Buzz Heats Up On MASH Progress, FDA Nod For New Trials: Stock Jumps After Q4 Print ↗

February 27, 2025

The company plans to unveil details at its virtual R&D Day on March 13.

Via Stocktwits

This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

January 08, 2025

Via Benzinga

Mastering Market Chaos: StoryTrading’s Top 5 Stocks You Can’t Ignore ↗

December 20, 2024

The trading landscape is alive with opportunity, shaped by a mix of macroeconomic events and sector-specific moves.

Via Talk Markets

Topics Stocks / Equities

Pure Storage Posts Upbeat Results, Joins Cross Country Healthcare, Marvell Technology, Stoke Therapeutics And Other Big Stocks Moving Higher On Wednesday ↗

December 04, 2024

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 13, 2024

Via Benzinga

Tyson Foods Posts Better-Than-Expected Earnings, Joins Shopify, Sea, Buckle And Other Big Stocks Moving Higher On Tuesday ↗

November 12, 2024

Via Benzinga

This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

November 12, 2024

Via Benzinga

MarketBeat Week in Review – 11/4 - 11/8

November 09, 2024

Markets rallied strongly this week on clarity about the election and an expected rate cut, but next week's inflation readings will determine if momentum lasts

Via MarketBeat

Topics Economy Government

How Altimmune Could Grab a Big Chunk of the GLP-1 Market

November 08, 2024

Altimmune is working on a developmental weight loss drug that could have strong benefits for an important segment of GLP-1 users.

Via MarketBeat

Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names ↗

October 11, 2024

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns.

Via Benzinga

1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc) ↗

September 17, 2024

Telemedicine once seemed like it was going to revolutionize healthcare.

Via The Motley Fool

3 Promising Biotech Stocks for the Long-Term: August 2024 ↗

August 13, 2024

Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Here are just a few.

Via InvestorPlace

The 7 Best Under $10 Stocks to Buy in August 2024 ↗

August 11, 2024

Buying low-priced stocks carries risk, but lower interest rates may lower the risk premium on these best stocks under $10.

Via InvestorPlace

Prediction: This Weight Loss Stock Will Be Acquired Within the Next Year ↗

August 09, 2024

Altimmune is a little-known pharmaceutical company looking to disrupt the weight loss space.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Altimmune, Inc. - Common Stock (NQ:ALT)

All News about Altimmune, Inc. - Common Stock

Resources